Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial-Reference-Cited by-同舟云学术

Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial

Published:2013-08-08 Issue:8 Volume:8 Page:e73639
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Nishijima Takeshi,Gatanaga Hiroyuki,Shimbo Takuro,Komatsu Hirokazu,Endo Tomoyuki,Horiba Masahide,Koga Michiko,Naito Toshio,Itoda Ichiro,Tei Masanori,Fujii Teruhisa,Takada Kiyonori,Yamamoto Masahiro,Miyakawa Toshikazu,Tanabe Yoshinari,Mitsuya Hiroaki,Oka Shinichi,

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference46 articles.

1. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV;JE Gallant;N Engl J Med,2006

2. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial;JE Gallant;JAMA,2004

3. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study;H Izzedine;Nephrol Dial Transplant,2005

4. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years;MR Nelson;AIDS,2007

5. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis;JR Arribas;J Acquir Immune Defic Syndr,2008

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risks and benefits of reducing the number of drugs to treat HIV-1 infection;Expert Opinion on Drug Safety;2021-02-24

2. Nucleos(t)ide reverse transcriptase inhibitor-sparing regimens in the era of standard 3-drug combination therapies for HIV-1 infection;Global Health & Medicine;2020-12-31

3. Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina;Revista Española de Quimioterapia;2020-12-03

4. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL: does estimated glomerular filtration rate matter?;International Journal of Antimicrobial Agents;2020-12

5. Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study;Open Forum Infectious Diseases;2020-08-13